Cardiovascular Risk

Primary Aldosteronism – Wide Spectrum of Clinical Manifestations

by Prateek Chopra | June 8, 2026 | Cardiology Conferences | ESH 2026 Cardiovascular Impact of PA: Primary aldosteronism (PA) is a common, potentially curable cause of secondary hypertension. Aldosterone excess contributes to cardiovascular morbidity beyond the effects of elevated blood pressure alone, including stroke, coronary artery disease, atrial fibrillation, heart failure, left ventricular hypertrophy, arterial stiffness, and target-organ damage. Illustrative […]

Primary Aldosteronism – Wide Spectrum of Clinical Manifestations Read Post »

Leave a Comment / ESH Day 2 / / / , , , , ,

Blood Pressure Variability: A Powerful Predictor of Cardiovascular and Cognitive Risk

by Prateek Chopra | June 2, 2026 | Cardiology Conferences | ESH 2026 Prognostic Significance of BP Variability: Blood pressure variability (BPV) is an important and modifiable cardiovascular risk marker beyond mean BP. Higher visit-to-visit systolic BP variability is linked to increased risks of CVD, stroke, heart failure, CKD, dementia, and all-cause mortality. Evidence: Clinical Implications: Monitoring and managing BP variability

Blood Pressure Variability: A Powerful Predictor of Cardiovascular and Cognitive Risk Read Post »

Leave a Comment / ESH Day 1 / / / , , , ,

Nocturnal Blood Pressure in Hypertension: Key Insights from the ESH 2026 Guidelines

by Prateek Chopra | June 1, 2026 | Cardiology Conferences | ESH 2026 Clinical Background: Nocturnal blood pressure (BP) assessment is critical for hypertension management and cardiovascular risk prediction. Elevated night-time BP is an independent risk factor for adverse cardiovascular outcomes, even in individuals with normal daytime BP. Nocturnal hypertension frequently coexists with obstructive sleep apnea (OSA), CKD, obesity, diabetes, autonomic

Nocturnal Blood Pressure in Hypertension: Key Insights from the ESH 2026 Guidelines Read Post »

Leave a Comment / ESH Day 1 / / / , , , ,

Inflammation, Body Mass Index, and Cardiovascular Outcomes in Chronic Kidney Disease and Type 2 Diabetes

by Prateek Chopra | July 3, 2026 | Diabetes Conferences | ADA 2026 Cardiovascular Risk Assessment Methods Study Population Key Findings Effect of Finerenone Clinical Implications Low-grade inflammation and obesity jointly contribute to cardiovascular risk in CKD and T2D. Finerenone maintained consistent cardioprotective benefits across all hsCRP and BMI categories, supporting its use for cardiovascular risk reduction in this high-risk

Inflammation, Body Mass Index, and Cardiovascular Outcomes in Chronic Kidney Disease and Type 2 Diabetes Read Post »

Leave a Comment / Diabetes Conferences / / / , , , ,

ABC Transporters as Surrogate Biomarkers of HDL Functionality for EarlyAtherosclerosis Risk Assessment in Type 2 Diabetes Mellitus

by Prateek Chopra | June 24, 2026 | Diabetes Conferences | ADA 2026 Clinical Significance Study Population Methods ABC Transporter Levels and HDL Functionality Impact on HDL Functionality Discriminatory Performance Clinical Implications Individuals with T2DM, particularly those with atherosclerosis, exhibited impaired HDL functionality despite similar HDL-C levels. Lower circulating ABCA1 and ABCG1 levels were associated with reduced cholesterol efflux capacity,

ABC Transporters as Surrogate Biomarkers of HDL Functionality for EarlyAtherosclerosis Risk Assessment in Type 2 Diabetes Mellitus Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , ,

Imaging: Incorporating Imaging Findings into Risk Assessment andPrevention Strategies

by Prateek Chopra | June 13, 2026 | Diabetes Conferences | ADA 2026 | 0 comments Cardiovascular Risk in Diabetes: Impact of Cardiovascular Disease in Diabetes: Role of Coronary Artery Calcification (CAC): Evidence from Clinical Studies: Guideline Recommendations: Additional Risk Stratification Considerations: Clinical Implications: Imaging findings, particularly coronary artery calcification, provide valuable information for cardiovascular

Imaging: Incorporating Imaging Findings into Risk Assessment andPrevention Strategies Read Post »

Leave a Comment / Diabetes Conferences / / / , , , ,

Biomarkers: Which Ones Are Worthwhile? (Personalised Risk)

by Prateek Chopra | June 11, 2026 | Diabetes Conferences | ADA 2026 | 0 comments Background: Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in individuals with type 2 diabetes (T2D), despite advances in risk factor management. Accurate risk stratification is essential to identify high-risk individuals and guide personalized preventive strategies.

Biomarkers: Which Ones Are Worthwhile? (Personalised Risk) Read Post »

Leave a Comment / Diabetes Conferences / / / , , , ,

PCE, PREVENT, SCORE2-Diabetes: Understanding the CVD Risk Prediction Tools in People with Diabetes

by Prateek Chopra | June 11, 2026 | Diabetes Conferences | ADA 2026 | 0 comments Need for Improved Risk Assessment: PREVENT Risk Equations: Diabetes and CKD-Specific Risk Stratification: SCORE2-Diabetes Model: Validation and Clinical Relevance: PREVENT and SCORE2-Diabetes represent important advances in cardiovascular risk prediction for people with diabetes. By incorporating diabetes-specific factors and broader

PCE, PREVENT, SCORE2-Diabetes: Understanding the CVD Risk Prediction Tools in People with Diabetes Read Post »

Leave a Comment / Diabetes Conferences / / / , , , ,
Scroll to Top